Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Langer

Showing results (501-510 of 596) with videos related to

Pageof 60
Sort By:
JCO Precision Oncology|June 7, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyJeffrey C Thompson, Erica L Carpenter, Benjamin A Silva, et al.
Science (New York, N.Y.)|June 20, 2024
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patientsDivij Mathew, Melina E Marmarelis, Caitlin Foley, et al.
JTO Clinical and Research Reports|April 8, 2022
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot StudyJeffrey C Thompson, Charu Aggarwal, Janeline Wong, et al.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
Journal of Geriatric Oncology|April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancerJulie A Kish, Qiang Zhang, Corey J Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2023
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerNikhil Yegya-Raman, Abigail T Berman, Christine A Ciunci, et al.
Cancer|January 31, 2024
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab eraMichelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JCO Oncology Practice|July 3, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical TrialMelina E Marmarelis, Dylan G Scholes, Tara L McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2016
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with ChemotherapyDaniel H Sterman, Evan Alley, James P Stevenson, et al.
Pageof 60

Showing results (501-510 of 596) with videos related to

Sort By:
Pageof 60
JCO Precision Oncology|June 7, 2021
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyJeffrey C Thompson, Erica L Carpenter, Benjamin A Silva, et al.
Science (New York, N.Y.)|June 20, 2024
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patientsDivij Mathew, Melina E Marmarelis, Caitlin Foley, et al.
JTO Clinical and Research Reports|April 8, 2022
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot StudyJeffrey C Thompson, Charu Aggarwal, Janeline Wong, et al.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
Journal of Geriatric Oncology|April 5, 2021
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancerJulie A Kish, Qiang Zhang, Corey J Langer, et al.
International Journal of Radiation Oncology, Biology, Physics|August 31, 2023
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung CancerNikhil Yegya-Raman, Abigail T Berman, Christine A Ciunci, et al.
Cancer|January 31, 2024
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab eraMichelle Iocolano, Nikhil Yegya-Raman, Cole Friedes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
JCO Oncology Practice|July 3, 2024
Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical TrialMelina E Marmarelis, Dylan G Scholes, Tara L McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2016
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with ChemotherapyDaniel H Sterman, Evan Alley, James P Stevenson, et al.
Pageof 60